<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141276">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960283</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN09-AM/MUCIS</org_study_id>
    <nct_id>NCT01960283</nct_id>
  </id_info>
  <brief_title>Methotrexate in the Treatment of Chronic Idiopathic Urticaria</brief_title>
  <acronym>MUCIS</acronym>
  <official_title>Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic urticaria is defined by urticarial lesions persisting at 6 weeks. The cause is not
      found in about 75% of cases (chronic idiopathic urticaria). The gold standard treatment
      consists of anti-H1 molecules. In severe cases, refractory to anti-H1, few therapeutic
      alternatives exist. Methotrexate, which is not expensive and often prescribed by
      dermatologists, has been efficiently tried in an open study on severe chronic idiopathic
      urticaria, and also in few case reports.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic urticaria, defined by its persistence beyond 6 weeks, is a common condition (0.1% to
      3% of the general population), occurring at any age. The etiology is not found in nearly 75%
      of cases (chronic idiopathic urticaria). Chronic idiopathic urticaria may resolve over
      several months or years. The quality of life of patients is usually strongly spoiled. The
      gold standard treatment consist of anti-H1 molecules. In severe cases, which are refractory
      to anti-H1, few therapeutic alternatives exist. Two studies have shown a benefit when adding
      to anti-H1, montelukast, anti-leukotriene, or cyclosporine. Methotrexate, which is another
      immunosuppressive drug, cheap and commonly prescribed by dermatologists, has been efficient
      in severe chronic urticaria, in an open study and in few case reports.

      Methotrexate, an anti-metabolite drug which inhibits dihydrofolate reductase, is indicated
      in hematologic malignancies and in autoimmune diseases. It may be given by oral or
      parenteral administration, once a week, and requires regular monitoring of renal and hepatic
      function, and blood count.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with complete remission of urticaria at 18 weeks</measure>
    <time_frame>at 18 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with complete remission of urticaria at 18 weeks, defined as no urticarial lesion 30 days before W18</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance : clinical and biological safety</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with clinical adverse effects Number of patients with biological adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment in improving symptoms : pruritus</measure>
    <time_frame>18 weeks and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with :
- pruritus At 18 weeks and 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistency of the complete remission at 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with persistency of the complete remission, defined as no urticarial lesion from the withdrawal of treatment until W26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment in improving symptoms : outbreaks by week</measure>
    <time_frame>18 weeks and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>- number of outbreaks by week/patient At 18 weeks and 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment in improving symptoms : duration of lesions</measure>
    <time_frame>18 weeks and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>- mean +/- standard deviation duration of lesions At 18 weeks and 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment in improving quality of life</measure>
    <time_frame>18 weeks and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean DLQI (quality of life) score :
At 18 weeks and 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment in improving quality of sleep</measure>
    <time_frame>18 weeks and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean score of quality of sleep (from 0 to 100) At 18 weeks and 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment in improving facial/cervical urticarial lesions</measure>
    <time_frame>18 weeks and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with, either :
facial/cervical urticarial lesions
urticarial lesions on the body only
facial/cervical + body lesions Indeed, facial or cervical urticarial lesions are considered more disturbing. At W18 and W26</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Chronic Urticaria</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group I will receive the intervention :
Methotrexate + anti-H1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The intervention in group II will include : placebo + anti-H1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (Novatrex ®) + anti-H1</intervention_name>
    <description>Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.
After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.
For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group.</description>
    <arm_group_label>Group I</arm_group_label>
    <other_name>Methotrexate</other_name>
    <other_name>Anti-H1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + anti-H1</intervention_name>
    <description>Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.
For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group.</description>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Placebo of methetrexate + anti-H1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who met the diagnostic criteria for chronic idiopathic urticaria, previously
        treated by

          -  3 different molecules of anti-H1 or

          -  a combination of 2 different molecules of anti-H1 or

          -  1 molecule of anti-H1 with at least a double dose for a total treatment duration of ≥
             3 months before inclusion

          -  With persistency of at least 7 days with urticarial lesions in the previous month

        Exclusion Criteria:

          -  Differential diagnosis of chronic idiopathic urticaria (urticarial vasculitis)

          -  Treatment with montelukast or immunosuppressive drugs during the previous month

          -  Contraindications to methotrexate

               -  Allergy to methotrexate

               -  Treatment which are contraindicated with methotrexate

               -  Pregnancy, possibility of getting pregnant (no effective contraception),
                  breastfeeding

               -  Anomalies in liver function (transaminases or liver failure at a rate 1.5 X
                  normal)

               -  Severe renal impairment (creatinine clearance calculated by the cockcroft
                  formula &lt;50 ml / min)

               -  Chronic respiratory failure

               -  Active infectious chronic diseases (viral hepatitis, HIV)

               -  History of neoplasia

               -  Mental deficiency

               -  Involvement in another drug clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annabel MARUANI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tours, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahtab SAMIMI, MD</last_name>
    <phone>33 2 47 47 90 80</phone>
    <email>samimi.mahtab@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine FOULON</last_name>
    <phone>33 2 47 47 46 33</phone>
    <email>christine.foulon@med.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU BREST Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MISERY, Dr</last_name>
      <phone>+33(0)298223315</phone>
      <email>laurent.misery@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent MISERY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie CONTIOS-ROGUEDAS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire ABASQ, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nolwenn COQUART, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie BRENAUT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHOSIDOW, Pr</last_name>
      <phone>+33(0)149812501</phone>
      <email>olivier.chosidow@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Germaine GABISON, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie BENETON, Dr</last_name>
      <phone>+33(0)243434358</phone>
      <email>nbeneton@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé MAILLARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CELERIER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion FENOT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corina BARA-PASSOT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU LILLE Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine STAUMONT-SALLE, Dr</last_name>
      <phone>+33(0)320444193</phone>
      <email>Delphine.SALLE@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Emeline PAPE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU NANCY Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick BARBAUD, Pr</last_name>
      <phone>+33(0)383711545</phone>
      <email>a.barbaud@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Julie WATON, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François CUNY, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire BERNIER, Dr</last_name>
      <phone>+33(0)240084116</phone>
      <email>claire.bernier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Sébastien BARBAROT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène AUBERT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital TENON</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angèle SORIA, Pr</last_name>
      <phone>+33(0)156017000</phone>
      <email>selim.aractingi@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle AMSLER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU POITIERS La Miléterie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard GUILLET, Dr</last_name>
      <phone>+33(0)549444400</phone>
      <email>gerard.guillet@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Gérard GUILLET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa WIERZBICKA, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Reims</name>
      <address>
        <city>Reims</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne GRANGE-PRUNIER, Dr</last_name>
      <phone>+33(0326784367</phone>
      <email>agrange@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Ziad REGUAI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe BERNARD, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU RENNES Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri ADAMSKI, Dr</last_name>
      <phone>+33(0)299284349</phone>
      <email>henri.adamski@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Henri ADAMSKI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain DUPUY, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette MIQUEL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine DROITCOURT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annabel MARUANI, Dr</last_name>
      <phone>+33(0)247479076</phone>
      <email>annabel.maruani@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Annbel MARUANI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent MACHET, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyrille HOARAU, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahtab SAMIMI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle LE BIDRE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriela GEORGESCOU, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie LE FOURN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
